SCHEMBL1160437

SCHEMBL1160437

O=C(NS(=O)(=O)c1ccccc1)c1cccc2c1nc(Cc1ccccc1)n2Cc1ccc(Cl)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 8/20 0.50
FLT4 P35916 8/20 0.50
KDR P35968 8/20 0.50
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46
PPARG P37231 6/20 0.45
CCR2 P41597 1/20 0.44
POLB P06746 1/20 0.44
LMNA P02545 1/20 0.44
GNRHR P30968 1/20 0.42
VDR P11473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1160320 0.92 ALOX5AP (0.47) FLT1FLT4KDRTP53PPARG
SCHEMBL1160397 0.86 FLT1 (0.53) FLT1FLT4KDRPPARGCCR2
Hydrochloric Acid SCHEMBL6171228 0.86 FLT1 (0.52) FLT1FLT4KDRPPARGCCR2
SCHEMBL1160435 0.83 GNRHR (0.51) FLT1FLT4KDRTP53MAPT
SCHEMBL1178232 0.83 PPARG (0.53) FLT1FLT4KDRTP53MAPT
SCHEMBL27507797 0.80 LMNA (0.43) TP53MAPTPPARGPOLBLMNA
SCHEMBL1160053 0.78 ALOX5AP (0.49) FLT1FLT4KDRTP53PPARG
SCHEMBL1160318 0.76 TP53 (0.51) TP53PPARGCCR2LMNA
SCHEMBL1160351 0.76 TP53 (0.51) TP53PPARGCCR2POLBLMNA
SCHEMBL1160410 0.75 EGFR (0.53) FLT1FLT4KDRPPARGCCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140024692-A1 Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma AESTUS THERAPEUTICS, INC. (US) 2014-01-23 US disclosed
US-8563589-B2 Methods of treating neuropathic pain with benzimidazole derivative agonists of PPARgamma SAMEEVE CORP 2013-10-22 US disclosed
EP-2459192-A1 METHODS OF TREATING NEUROPATHIC PAIN WITH BENZIMIDAZOLE DERIVATIVE AGONISTS OF PPARGAMMA Aestus Therapeutics, Inc. (US) 2012-06-06 EP disclosed
WO-2011014600-A1 METHODS OF TREATING NEUROPATHIC PAIN WITH BENZIMIDAZOLE DERIVATIVE AGONISTS OF PPARGAMMA AESTUS THERAPEUTICS, INC. (US) 2011-02-03 WO disclosed
US-20110028527-A1 Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma AESTUS THERAPEUTICS, INC. (US) 2011-02-03 US disclosed
EP-0882718-B1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-08-31 EP disclosed
US-6352985-B1 CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-03-05 US disclosed
US-6166219-A Benzimidazole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-12-26 US disclosed
EP-0882718-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024692-A1 Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma PPARG, PPARA, PPARD FLT1 4300/4885FLT4 3260/4885KDR 4218/4885
US-20110028527-A1 Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma PPARG, PPARA, PPARD FLT1 4300/4885FLT4 3260/4885KDR 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.